Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting now

Conditions studied: Primary Breast Cancer, Recurrent/Metastatic Breast Cancer

In brief

Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: * To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression

Key facts

Study ID
NCT01840293
Run by
Cancer Trials Ireland
People needed
1780
Starts
2013-02-01
Expected to finish
2038-01-01
Last updated by the study team
2025-12-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.